Blogs & News
Linden Lake Labs Portfolio Company CrossBridge Bio to Be Acquired by Eli Lilly and Company
- Press Release
CrossBridge Bio to be acquired by Eli Lilly and Company for up to $300 million, marking an early platform milestone for Linden Lake Labs.
Xcellon Biologics Launches Xcellerate Program to Support Early-Stage Biotech Innovation
- Press Release
Xcellon Biologics launches Xcellerate, a program designed to help early-stage biotech companies accelerate ADC development and navigate the toughest phase between proof-of-concept and funding.
IntoCell and Xcellon Biologics Partner to Expand Access to Next-Generation ADC Technologies
- Press Release
Xcellon Biologics partners with IntoCell to expand linker-payload toolbox
Antibody Drug Conjugate CDMO Xcellon partners with Invenra
- Press Release
Invenra’s multispecific antibody platforms, together with Xcellon’s bioconjugation and manufacturing expertise, are advancing the development of complex biologics.
TEDCO Equitech Growth Fund awarded Xcellon Biologics
- News
Xcellon aligns with Maryland's TEDCO EGF for future biologics development and manufacturing.
From Global Pharma to Maryland’s Next-Gen CDMO: Yuk Chun Chiu’s Vision for Xcellon Biologics
- News
BioBuzz interviewed with Yuk Chun Chiu, Xcellon's COO on the vision and journey of the company
Upcoming Events
Xcellon is sponsoring World ADC 2025
Xcellon Biologics is proud to sponsor the World ADC 2025. Come visit our booth and see our latest development in conjugation technologies and gene to IND service offerings!
- 11/03/2025
- — 11/06/2025
Partner
With Us
Partner With Us
Xcellon Biologics is backed by successful biotech entrepreneurs and professionals from top pharmaceutical and CDMO companies including Lonza, Abzena, Amgen, MedImmune, AstraZeneca, BioNTech, Seattle Genetics, and Immunomedics.
We collaborate with leading innovators and global partners to accelerate biopharmaceutical breakthroughs while maintaining the highest quality and regulatory standards.
